{QTtext}{timescale:100}{textBox: 0, 0, 45, 0}{font:Arial}{size:16}{backColor:0,0,0}
{textColor:65535,65535,65535}{width:640}{height:40}{justify:Center}


[00:00:00.00]
<<MUSIC PLAYING>>

[00:00:02.13]
All of us in cancer
research, as well as
[00:00:04.92]
clinicians, our first
goal in treating a patient
[00:00:07.98]
is get them into
remission, which
[00:00:10.11]
means all evidence
of cancer goes away.
[00:00:12.48]
The second step is making
sure that disease never
[00:00:15.06]
comes back again.

[00:00:15.97]
Hi.

[00:00:16.47]
My name is Tom Loughran.

[00:00:17.55]
I'm director of the University
of Virginia Cancer Center.
[00:00:20.88]
My research interest
is on LGL leukemia.
[00:00:23.58]
What I'd like to do
today is tell you
[00:00:25.23]
a little bit about
the illness, why
[00:00:27.63]
I think it would be important
for you to see me here,
[00:00:29.85]
if at all possible,
and then give you
[00:00:32.19]
some idea of our ongoing
research in this illness.
[00:00:35.49]
I discovered LGL
leukemia back in Seattle
[00:00:38.52]
when I was a fellow
about 30 years ago.
[00:00:41.59]
It's a fairly rare disease.

[00:00:43.59]
It's characterized by
having too many LGL
[00:00:46.44]
cells, which are clonal.

[00:00:48.96]
Clonal means that one
cell became abnormal,
[00:00:51.88]
and then it copies itself
over and over again.
[00:00:55.02]
Our patients become sick by
having either too low blood
[00:00:58.74]
counts or having
autoimmune diseases
[00:01:01.29]
like rheumatoid arthritis.

[00:01:03.31]
Our LGL Leukemia Registry is
really a worldwide registry
[00:01:07.05]
to capture clinical
information about our patients.
[00:01:10.62]
Our research is
very comprehensive.
[00:01:12.96]
It's organized
around the registry
[00:01:15.36]
itself, our laboratory,
and then clinical trials.
[00:01:20.53]
So in conclusion,
the overarching goal
[00:01:23.22]
of our research program is to
understand the pathogenesis
[00:01:28.47]
or causes of LGL
leukemia much better
[00:01:31.41]
so that we can define the
illness better, but most
[00:01:35.73]
importantly, come up with
better treatment options.
[00:01:38.37]
Right now, we have
medicines that act broadly
[00:01:42.09]
to suppress the immune system.

[00:01:44.31]
They are very effective in
controlling LGL leukemia,
[00:01:48.03]
but so far,
unfortunately to date,
[00:01:50.40]
we have no therapy that
can cure this illness.
[00:01:53.01]
<<MUSIC PLAYING>>

[00:01:56.36]


[00:02:00.44]